Key metrics and charts across all fundamental categories.
Stock price and market valuation
BIO trades at $284.67, a 16.9% increase year-over-year. Market capitalization stands at $7.67B, up 12.8% from the prior year. Track BIO price trends and market cap history to understand how the market values this company over time.
Revenue and earnings growth across quarters
$2.59B in TTM revenue grew 1.9% YoY, reaching $592.10M last quarter. TTM EBITDA of $57.60M on operating income of $34.10M shows growth is flowing through. Net income of $168.80M TTM confirms the company is converting revenue into profit. Revenue is growing modestly — monitor for acceleration or deceleration.
Assets, cash, debt, and leverage
With $9.79B in assets and $802.90M in long-term debt, the D/E of 0.1 shows a conservative capital structure — the company has a strong financial cushion to weather downturns.
Price multiples and return ratios
At 45.5x P/E, the stock trades at a premium — the market expects above-average growth. P/S of 3.0x and P/B of 1.1x provide additional context. The premium P/E is not backed by strong revenue growth — the stock may be overvalued.
Operating efficiency and return metrics
Op. margin of 5.8% is up 1.7% YoY — cost efficiency is improving. Net margin at -89.0%. ROE of 2.5% shows the company generates solid returns on shareholder equity.
Free cash flow, earnings quality, and capital allocation
FCF of $78.10M on $108.10M in operating cash flow. The FCF / Net Income ratio of 0.5x indicates partial cash conversion — earnings quality needs attention. Cash reserves of $507.20M provide financial flexibility. Shares outstanding declined 3.5% YoY — buybacks are returning capital to shareholders.
